Black Diamond Therapeutics, Inc., a biotechnology company, discover and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an irreversible small molecule inhibitor that is designed to block the function of family of oncogenic proteins defined by driver mutations across a range of tumor types, and which affect the epidermal growth factor receptor (EGFR), the tyrosine-protein kinase, or human epidermal growth factor receptor 2. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including allosteric and canonical EGFR mutations; and various early stage pipeline programs of allosteric mutations in kinases related to cancer and/or rare genetic diseases. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
IPO Year: 2020
Exchange: NASDAQ
Website: blackdiamondtherapeutics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/31/2024 | $20.00 | Outperform | Raymond James |
| 7/14/2023 | Overweight | Piper Sandler | |
| 6/30/2023 | $2.00 → $10.00 | Hold → Buy | Stifel |
| 6/28/2023 | $11.00 | Neutral → Buy | H.C. Wainwright |
| 6/27/2023 | $10.00 | Neutral → Outperform | Wedbush |
| 3/29/2022 | Outperform → Neutral | Wedbush | |
| 3/22/2022 | Buy → Neutral | H.C. Wainwright | |
| 9/30/2021 | $10.00 | Hold | Stifel |